CDT Equity Inc. (CDT)
CDT trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.
Profile
| Field | Value |
|---|---|
| Ticker | CDT on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2022 |
| SEC CIK | 0001896212 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials
Not reported in SEC XBRL data.
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "These factors raise substantial doubt regarding the Company's ability to continue as a going concern for at least the next 12 months from the financial statement filing date." | 10-Q 2026-08-12 |
| Cash and burn | $747K cash; operating cash flow -$2.9M a quarter. | Report 2026-06-30 |
| Shares outstanding | 1,573,340 (2026-08-12); 3,062,025,000 a year earlier; 72,813,776,000 three years earlier. 1y figure adjusted for splits (1-for-2000 overall); 3y figure adjusted for splits (1-for-3000000 overall). | Cover page 2026-08-12 |
| Reverse splits, 3 years | 7; latest 1-for-20 on 2026-11-06 | Source 2026-11-06 |
| Shelf and offerings, 12 months | 2 S-3/F-3 shelf filings; 1 424B5 takedowns | Latest 2026-04-02 |
| Exchange deficiency notices, 12 months | 1 (8-K item 3.01) | 8-K 2026-05-28 |
| Auditor | CBIZ CPAs P.C., New York, New York, United States; changed auditors 2 times in 24 months | 8-K 4.01 2026-06-29 |
| Late filings, 12 months | 2 NT notices | NT 10-Q 2026-05-15 |
| Insider trades, 12 months | Bought $0, sold $2.9M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
| Market cap check | The listing's market cap implies 1,017,862 shares at the 2026-11-13 price; the latest SEC cover count is 1,573,340 as of 2026-08-12, 1,573,340 after the 1-for-25 and 1-for-20 splits since. The SEC count is the older of the two, so the listing's cap is likely the current one; shares were issued since that cover page. | Nasdaq screener and SEC cover page |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q2 2026 2026-06-30 | Not filed | -$4.6M | -$544K | $747K | No debt tags | Needs four quarters | 10-Q 2026-08-12 |
| Q1 2026 2026-03-31 | Not filed | -$4.1M | -$1.9M | $97K | No debt tags | Needs four quarters | 10-Q 2026-07-15 |
| Q4 2025 2025-12-31 | Not filed | -$21.3M | -$4.6M | $1.5M | No debt tags | Needs four quarters | 10-K 2026-04-15 |
| Q3 2025 2025-09-30 | Not filed | -$7.1M | -$4.4M | $3.8M | No debt tags | Needs four quarters | 10-Q 2025-11-13 |
| Q2 2025 2025-06-30 | Not filed | -$6.0M | -$2.6M | $3.3M | No debt tags | Needs four quarters | 10-Q 2026-08-12 |
| Q1 2025 2025-03-31 | Not filed | -$4.8M | -$3.9M | $2.1M | No debt tags | Needs four quarters | 10-Q 2026-07-15 |
| Q4 2024 2024-12-31 | Not filed | -$2.4M | -$3.8M | $554K | $1.8M | Needs four quarters | 10-K 2026-04-15 |
| Q3 2024 2024-09-30 | Not filed | -$6.5M | -$2.0M | $71K | $2.5M | Needs four quarters | 10-Q 2025-11-13 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B3 | 2026-11-16 |
| Latest annual report | 10-K | 2026-04-15 |
| Latest quarterly / interim | 10-Q | 2026-11-16 |
| Latest current report | 8-K | 2026-11-16 |
| Latest proxy | DEF 14A | 2026-10-27 |
Source: SEC EDGAR submissions feed, 374 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -69.5% |
| 1 month | -95.6% |
| 3 months | -100.0% |
| Year to date | -100.0% |
| 1 year | -100.0% |
| From 52-week high | -100.0% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Other listings for this company
| Ticker | Name | Price |
|---|---|---|
| CDTTW | CDT Equity Inc. Warrant | $0.0070 |
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| LABT | Lakewood-Amedex Biotherapeutics Inc. | $0.2194 | -22.31% | $520K |
| SPRC | SciSparc Ltd. | $0.3307 | -10.62% | $815K |
| OGEN | Oragenics Inc. | $0.1980 | -1.49% | $893K |
| MTNB | Matinas Biopharma Holdings Inc. | $0.9270 | +3.00% | $908K |
| GOVX | GeoVax Labs Inc. | $2.02 | +18.48% | $1.1M |
| BDRX | Biodexa Pharmaceuticals plc American Depositary Shs | $2.24 | -6.28% | $1.2M |
| ELAB | PMGC Holdings Inc. | $1.66 | +5.06% | $1.3M |
| KAPA | Kairos Pharma Ltd. | $0.4069 | -10.30% | $1.4M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier